SCHEMBL26792

SCHEMBL26792

COc1cc(NS(=O)(=O)c2ccc3c(ccn3C)c2)cc(OC)c1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.61
HTT P42858 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
TUBB4A P04350 1/20 0.53
TUBB P07437 1/20 0.53
TUBA3C P0DPH7 1/20 0.53
TUBA1B P68363 1/20 0.53
TUBA4A P68366 1/20 0.53
TUBB4B P68371 1/20 0.53
TUBB3 Q13509 1/20 0.53
TUBB2A Q13885 1/20 0.53
TUBB8 Q3ZCM7 1/20 0.53
TUBA3E Q6PEY2 1/20 0.53
TUBA1A Q71U36 1/20 0.53
TUBA1C Q9BQE3 1/20 0.53
TUBB6 Q9BUF5 1/20 0.53
TUBB2B Q9BVA1 1/20 0.53
TUBB1 Q9H4B7 1/20 0.53
SIRT6 Q8N6T7 1/20 0.52
LMNA P02545 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6343382 0.90 PKM (0.61) PKMHTTSMN1; SMN2TUBB4ATUBB
SCHEMBL5423815 0.86 HTT (0.55) PKMHTTSMN1; SMN2LMNAMAPT
SCHEMBL31687126 0.85 PKM (0.64) PKMSMN1; SMN2SIRT6LMNAMAPT
SCHEMBL6340645 0.85 TUBB4A (0.56) PKMHTTSMN1; SMN2TUBB4ATUBB
SCHEMBL6352850 0.81 PKM (0.49) PKMHTTSMN1; SMN2TUBB4ATUBB
SCHEMBL6341219 0.77 LMNA (0.79) PKMHTTSMN1; SMN2LMNAMAPT
SCHEMBL6351710 0.77 TUBB4A (0.52) SMN1; SMN2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL9257125 0.77 PSEN1 (0.69) PKMSIRT6LMNA
SCHEMBL28051137 0.76 HTT (0.61) PKMHTTSMN1; SMN2LMNAMAPT
SCHEMBL2587301 0.76 PKM (1.00) PKMHTTSMN1; SMN2SIRT6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187246-A1 Cell proliferation inhibitors LI QUN (US) 2005-08-25 US claimed
EP-1181269-B1 CELL PROLIFERATION INHIBITORS ABBOTT LAB (US) 2004-02-25 EP claimed
US-20030096856-A1 Cell proliferation inhibitors ABBVIE INC. 2003-05-22 US claimed
US-20030078439-A1 Process for the preparation of cell proliferation inhibitors ABBVIE INC. 2003-04-24 US claimed
US-6521658-B1 Cell proliferation inhibitors ABBOTT LABORATORIES 2003-02-18 US claimed
WO-2002024648-A2 PROCESS FOR THE PREPARATION OF CELL PROLIFERATION INHIBITORS ABBOTT LABORATORIES (US) 2002-03-28 WO claimed
EP-1181269-A1 CELL PROLIFERATION INHIBITORS ABBOTT LABORATORIES (US) 2002-02-27 EP claimed
WO-2000073264-A1 CELL PROLIFERATION INHIBITORS ABBOTT LABORATORIES (US) 2000-12-07 WO claimed
EP-4620466-A1 TRIMETHOXYSTYRYL DERIVATIVES FOR USE IN THE TREATMENT OF PACLITAXEL-RESISTANT CANCER Instituto de Investigación Biomédica de Salamanca De la Fundación Instituto Ciencia de la Salud De Castilla y León (ES) 2025-09-24 EP disclosed
EP-3175870-A1 MEDICAL DEVICE HAVING HYDRATION INHIBITOR Abbott Laboratories (US) 2017-06-07 EP disclosed
EP-2301619-B1 Multiple drug delivery from a balloon and a prosthesis ABBOTT LAB (US) 2017-05-10 EP disclosed
EP-1536850-B1 MEDICAL DEVICE HAVING HYDRATION INHIBITOR ABBOTT LAB (US) 2016-08-10 EP disclosed
US-9296011-B2 Prosthesis having varied concentration of beneficial agent ABBOTT LABORATORIES (US) 2016-03-29 US disclosed
US-20150196692-A1 MULTIPLE DRUG DELIVERY FROM A BALLOON AND A PROSTHESIS ABBOTT LABORATORIES (US) 2015-07-16 US disclosed
US-20030096856-A1 Cell proliferation inhibitors ABBVIE INC. 2003-05-22 US disclosed
US-20030078439-A1 Process for the preparation of cell proliferation inhibitors ABBVIE INC. 2003-04-24 US disclosed
US-6521658-B1 Cell proliferation inhibitors ABBOTT LABORATORIES 2003-02-18 US disclosed
WO-2002024648-A2 PROCESS FOR THE PREPARATION OF CELL PROLIFERATION INHIBITORS ABBOTT LABORATORIES (US) 2002-03-28 WO disclosed
EP-1181269-A1 CELL PROLIFERATION INHIBITORS ABBOTT LABORATORIES (US) 2002-02-27 EP disclosed
WO-2000073264-A1 CELL PROLIFERATION INHIBITORS ABBOTT LABORATORIES (US) 2000-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078439-A1 Process for the preparation of cell proliferation inhibitors MKI67, CCNI, CDKN1A PKM 2047/4885HTT 1830/4885SMN1; SMN2 3964/4885
US-20030096856-A1 Cell proliferation inhibitors MKI67, CCNI, CCNA1 PKM 1894/4885HTT 4313/4885SMN1; SMN2 1869/4885
US-20050187246-A1 Cell proliferation inhibitors MKI67, CCNI, CCNC PKM 1733/4885HTT 4031/4885SMN1; SMN2 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.